Pfizer's RSV Vaccine Receives CDE Acceptance for Clinical Trial Application in China

Gelonghui June 3 | Public data from the Center for Drug Evaluation of the National Medical Products Administration shows that Pfizer's Respiratory Syncytial Virus (RSV) vaccine was submitted for clinical trial on June 1 and has been accepted.